Call for consensus in defining biological aging

We speak with a key contributor to the Longevity2020 online conference about biological aging.

UK start-up AgeCurve is focused on the measurement of aging and claims to be the first start-up to use direct-to-consumer personal proteomics to provide deep age profiles to end users. AgeCurve’s founder and director Attila Csordas is a Longevity biologist and philosopher with expansive ideas on biological aging.

His company is also developing a targeted proteomics COVID-19 home saliva test which can accurately detect presence of COVID-19 proteins in saliva by measuring peptide ions distinct to the COVID-19 proteins.

Longevity.Technology: Attila’s also a curator on Monday 27th April to the Longevity2020 session on ‘Defining biological aging’ alongside speakers such as Aubrey de Grey, Nir Barzilai and Lynne Cox.



In the session we’ll be addressing the need for candidate definitions from different, biological, clinical, logical and computational angles to adopt a consensus definition for biological aging.

How are traditional biomarkers like body composition, muscle strength and cognition complimented by the techniques of methylation, inflammation and epigenetic?


With so many opinions and options: how can scientists prove their technologies and investors invest with confidence? We’ll be using this session to assist in directing many of the other sessions taking place on Longevity2020.

This event is free and you can pre-register here.

Image credit: AgeCurve

Carla Heyworth
Carla is sub editor at Longevity.Technology and she's the glue that keeps the team on track and the articles rolling-out. She has an extensive background in B2B communications, events and marketing. Carla's a visual person and can often be found behind a camera or editing photos

Latest articles

Fountain’s ‘hypothesis-free’ approach to Longevity AI

We reached out to Fountain’s CEO John Dimos to see what more we can learn about the mysterious San Francisco start-up. When it comes to...

G3 and Juvenescence partner on deep learning venture

G3 Therapeutics and Juvenescence announce the formation of Juvenomics to apply deep molecular profiling and deep learning to tackle aging. Juvenomics, a joint venture between...

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.